The research showed that CD8+ T cells (yellow) activated by PD-1 blockade also interact with T regulatory cells (teal and red), which subsequently dampen the immune response against the melanoma tumor cells (blue). Credit: UC Irvine School of Medicine, Department of Physiology & Biophysics and Institute for Immunology Checkpoint immunotherapy utilizing PD-1 blockade has become the standard of care for metastatic melanoma. While this treatment is effective in 40% of patients, the other 60% develop resistance, leading to tumor regrowth. A multidisciplinary research team led by the University of California, Read More